|
1
|
Inamura K: Lung Cancer: Understanding its
molecular pathology and the 2015 WHO classification. Front Oncol.
7:1932017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McIntyre A and Ganti AK: Lung cancer-A
global perspective. J Surg Oncol. 115:550–554. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deng S, Calin GA, Croce CM, Coukos G and
Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell
Cycle. 7:2643–2646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang C, Chen YX, Wu NY, Yin JY, Li XP,
Huang HS, Zhang W, Zhou HH and Liu ZQ: MiR-488 inhibits
proliferation and cisplatin sensibility in non-small-cell lung
cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling
pathway. Sci Rep. 7:403842017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li T, Ding ZL, Zheng YL and Wang W:
MiR-484 promotes non-small-cell lung cancer (NSCLC) progression
through inhibiting Apaf-1 associated with the suppression of
apoptosis. Biomed Pharmacother. 96:153–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin L, Tu HB, Wu L, Liu M and Jiang GN:
MicroRNA-21 regulates non-small cell lung cancer cell invasion and
chemo-sensitivity through SMAD7. Cell Physiol Biochem.
38:2152–2162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin J, Wang M, Jin C and Qi Q: miR-101
sensitizes A549 NSCLC cell line to CDDP by activating caspase
3-dependent apoptosis. Oncol Lett. 7:461–465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jima DD, Zhang J, Jacobs C, Richards KL,
Dunphy CH, Choi WW, Au WY, Srivastava G, Czader MB, Rizzieri DA, et
al: Deep sequencing of the small RNA transcriptome of normal and
malignant human B cells identifies hundreds of novel microRNAs.
Blood. 116:e118–e127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang L, Qian J, Qiang Y, Huang H, Wang C,
Li D and Xu B: Down-regulation of miR-4500 promoted non-small cell
lung cancer growth. Cell Physiol Biochem. 34:1166–1174. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin Q, Zheng H, Xu J, Zhang F and Pan H:
LncRNA SNHG16 aggravates tumorigenesis and development of
hepatocellular carcinoma by sponging miR-4500 and targeting STAT3.
J Cell Biochem. Feb 18–2019.(Epub ahead of print) Doi:
10.1002/jcb.28440.
|
|
14
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harada D, Takigawa N and Kiura K: The role
of STAT3 in non-small cell lung cancer. Cancers (Basel). 6:708–722.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Fei D, Xing J and Du J:
MicroRNA-29a inhibits proliferation and induces apoptosis in
rheumatoid arthritis fibroblast-like synoviocytes by repressing
STAT3. Biomed Pharmacother. 96:173–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shan D, Shang Y and Hu T: MicroRNA-411
inhibits cervical cancer progression by directly targeting STAT3.
Oncol Res. 27:349–358. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun CC, Li SJ, Zhang F, Zhang YD, Zuo ZY,
Xi YY, Wang L and Li DJ: The novel miR-9600 suppresses tumor
progression and promotes paclitaxel sensitivity in non-small-cell
lung cancer through altering STAT3 expression. Mol Ther Nucleic
Acids. 5:e3872016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haghikia A, Hoch M, Stapel B and
Hilfiker-Kleiner D: STAT3 regulation of and by microRNAs in
development and disease. JAKSTAT. 1:143–150. 2012.PubMed/NCBI
|
|
20
|
Carraro G, El-Hashash A, Guidolin D,
Tiozzo C, Turcatel G, Young BM, De Langhe SP, Bellusci S, Shi W,
Parnigotto PP and Warburton D: miR-17 family of microRNAs controls
FGF10-mediated embryonic lung epithelial branching morphogenesis
through MAPK14 and STAT3 regulation of E-Cadherin distribution. Dev
Biol. 333:238–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wan LY, Woo CS, Turner PC, Wan JM and
El-Nezami H: Individual and combined effects of Fusarium toxins on
the mRNA expression of pro-inflammatory cytokines in swine jejunal
epithelial cells. Toxicol Lett. 220:238–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koller D and Friedman N: Probabilistic
Graphical Models: Principles and techniques-adaptive computation
and machine learning. Probabilistic graphical models-principles and
techniques. 2009.
|
|
23
|
Du WW, Ling F, Li M, Yang X, Liang Y, Peng
C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, et al: MicroRNA
miR-24 enhances tumor invasion and metastasis by targeting PTPN9
and PTPRF to promote EGF signaling. J Cell Sci. 126:1440–1453.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li S, Li Z, Guo F, Qin X, Liu B, Lei Z,
Song Z, Sun L, Zhang HT, You J and Zhou Q: miR-223 regulates
migration and invasion by targeting Artemin in human esophageal
carcinoma. J Biomed Sci. 18:242011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hong L, Han Y, Zhang H, Zhao Q and Qiao Y:
miR-210: A therapeutic target in cancer. Expert Opin Ther Targets.
17:21–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xia B, Li H, Yang S, Liu T and Lou G:
MiR-381 inhibits epithelial ovarian cancer malignancy via YY1
suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang C, Chen Q, Li S, Li S, Zhao Z, Gao H,
Wang X, Li B, Zhang W, Yuan Y, et al: Dual inhibition of PCDH9
expression by miR-215-5p up-regulation in gliomas. Oncotarget.
8:10287–10297. 2017.PubMed/NCBI
|
|
28
|
Danza K, De Summa S, Pinto R, Pilato B,
Palumbo O, Merla G, Simone G and Tommasi S: MiR-578 and miR-573 as
potential players in BRCA-related breast cancer angiogenesis.
Oncotarget. 6:471–483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu HY, Wang Y, Zhang H and Xu J: The long
non-coding RNA UCA1, as a prognostic biomarker for high grade
serous ovarian carcinoma. Eur J Gynaecol Oncol. 38:883–889.
2017.
|
|
30
|
Reinhart BJ, Slack FJ, Basson M,
Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Johnson CD, Esquela-Kerscher A, Stefani G,
Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J,
Shingara J, et al: The let-7 microRNA represses cell proliferation
pathways in human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu FY, Tu Y, Deng Y, Guo C, Ning J, Zhu Y,
Lv X and Ye H: MiR-4500 is epigenetically downregulated in
colorectal cancer and functions as a novel tumor suppressor by
regulating HMGA2. Cancer Biol Ther. 17:1149–1157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song L, Turkson J, Karras JG, Jove R and
Haura EB: Activation of Stat3 by receptor tyrosine kinases and
cytokines regulates survival in human non-small cell carcinoma
cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alvarez JV, Greulich H, Sellers WR,
Meyerson M and Frank DA: Signal transducer and activator of
transcription 3 is required for the oncogenic effects of
non-small-cell lung cancer-associated mutations of the epidermal
growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Looyenga BD, Hutchings D, Cherni I,
Kingsley C, Weiss GJ and Mackeigan JP: STAT3 is activated by JAK2
independent of key oncogenic driver mutations in non-small cell
lung carcinoma. PLoS One. 7:e308202012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al:
Mutations in the EGFR kinase domain mediate STAT3 activation via
IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yin Z, Zhang Y, Li Y, Lv T, Liu J and Wang
X: Prognostic significance of STAT3 expression and its correlation
with chemoresistance of non-small cell lung cancer cells. Acta
Histochem. 114:151–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
You S, Li R, Park D, Xie M, Sica GL, Cao
Y, Xiao ZQ and Deng X: Disruption of STAT3 by niclosamide reverses
radioresistance of human lung cancer. Mol Cancer Ther. 13:606–616.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Epling-Burnette PK, Liu JH,
Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang
JM, Yang-Yen HF, Karras J, et al: Inhibition of STAT3 signaling
leads to apoptosis of leukemic large granular lymphocytes and
decreased Mcl-1 expression. J Clin Invest. 107:351–362. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ivanov VN, Bhoumik A, Krasilnikov M, Raz
R, Owen-Schaub LB, Levy D, Horvath CM and Ronai Z: Cooperation
between STAT3 and c-jun suppresses Fas transcription. Mol Cell.
7:517–528. 2001. View Article : Google Scholar : PubMed/NCBI
|
